Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor

Area of Science:

• Biotechnology
• Oncology
• Molecular Biology

Background:

• Vascular Endothelial Growth Factor (VEGF) is a key driver of angiogenesis, essential for tumor growth.
• Monoclonal antibodies (mAbs) targeting VEGF inhibit tumor growth but face challenges in production and administration.
• Single-chain antibody fragments (scFvs) offer advantages for large-scale production and gene therapy applications.

Purpose of the Study:

• To develop and characterize anti-VEGF scFvs for potential therapeutic use.
• To evaluate the efficacy of these scFvs in preclinical models of angiogenesis-dependent diseases.

Main Methods:

• Generation of anti-VEGF scFvs using a human phage-display library.
• Assessment of anti-angiogenic activity by blocking chick embryo chorioallantoic membrane vascularization.
• Evaluation of tumor growth inhibition in nude mouse models with subcutaneous tumors.

Main Results:

• Successfully derived human anti-VEGF scFvs with potent anti-angiogenic properties.
• Demonstrated significant inhibition of chick embryo chorioallantoic membrane vascularization.
• Showed a reduction in subcutaneous tumor growth in nude mice treated with the anti-VEGF scFvs.

Conclusions:

• Anti-VEGF scFvs are effective inhibitors of angiogenesis and tumor growth.
• scFvs represent a viable alternative to mAbs for treating angiogenesis-dependent diseases.
• This research paves the way for gene therapy-based strategies utilizing scFvs for cancer treatment.